Global Oligonucleotide API Industry Anticipating a Striking US$ 5.36 Billion Surge with a Consistent 10.2% CAGR by 2030 | FMI

Global Oligonucleotide API Industry

The Global Oligonucleotide API Industry is on the brink of a significant breakthrough, with projections indicating an impressive growth trajectory from 2022 to 2030. According to the latest analysis by Future Market Insights (FMI), the market is set to experience a robust Compound Annual Growth Rate (CAGR) of 10.2%, reaching a remarkable valuation of US$ 5.36 billion by the end of the forecast period.

The driving force behind this remarkable surge is the escalating demand for innovative drug classes. As pharmaceutical companies seek novel therapeutic solutions, the Oligonucleotide API industry stands at the forefront, offering promising avenues for drug development. This growth is further underscored by the transition of over 100 oligonucleotide APIs through clinical trial phases, with regulatory approval imminent.

FMI’s comprehensive analysis unveils a promising landscape as these oligonucleotide APIs approach regulatory approval. Post-approval, there is a projected surge in the demand for production capacity, cementing the industry’s growth trajectory well into 2030. This expansion not only signifies economic growth but also underscores the industry’s crucial role in addressing the evolving needs of the pharmaceutical sector.

Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-11933

Apart from immune therapy, microbial and cardiovascular infections, and cancer, oligonucleotide APIs are being tried out to treat neurological disorders like Alzheimer’s as well. However, factors like regulatory complexities and timely delivery of oligonucleotides (amidst COVID-19) are acting as restraints.

Key Takeaways from Global Oligonucleotide API Industry Study

  • Antisense oligonucleotide APIs are anticipated to reach US$ 4 Bn by 2030.
  • North America and Europe collectively accounted for more than 47% of revenue share in 2019 while Asia Pacific is expected to grow at the fastest rate in the forecast period.
  • Increase in the use of antisense oligonucleotide APIs (especially post-approval from the US FDA in 2016) to boost the market in the forecast period

 “Inorganic mode of growth coupled with broad therapeutic applications in gene therapy is expected to bolster the Global Oligonucleotide API Industry,” says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.).

New Product Launches: Key Indicators to Global Oligonucleotide API Industry

FMI has analyzed players such as Akcea Therapeutics, Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., and Dynavax Technologies in this report. According to the analysis, these players are consolidating their positions through new product launches.

For instance –

  • In March 2020, Dynavax entered into a collaboration with Clover Biopharmaceuticals to develop a vaccine candidate to combat COVID-19. Clover is into advanced evaluation of its Covid-19 S-Trimer, protein-based coronavirus vaccine candidate and Dynavax has its technical expertise along with proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018 for executing this.
  • Alnylam Pharmaceuticals, Inc., in 2018, launched Givlaari and Onpattro at the commercial level.

Request Your Customized Report Now!
https://www.futuremarketinsights.com/customization-available/rep-gb-11933

Gene Therapy and Oligonucleotide APIs

Synthetic oligonucleotides are being used in gene therapy for inactivating genes that help in propagating the disease. Antisense oligonucleotide APIs are used for disrupting the faulty gene’s transcription.

Also, siRNA could be used for signaling the cell to disrupt faulty mRNA’s translation. Along these lines, Pharmamar, in Jan 2020, signed an agreement with Jazz Pharmaceuticals to sell the API for “lurbinectedin”, one of the late-phase treatments for SCLC (small cell lung cancer) so that the latter could commercialize it.

Key Segments of Global Oligonucleotide API Industry Survey: 

Global Oligonucleotide API Industry by API:

  • Antisense Oligonucleotides APIs
  • Short Interfering RNA (siRNA) APIs
  • Phosphorodiamidate Morpholino Oligonucleotides (PMO) APIs
  • MiRNA APIs
  • Aptamers APIs
  • CpG Oligonucleotides APIs
  • Others (ON Conjugates (NP), ShRNA, etc.)

Global Oligonucleotide API Industry by Marketing Status:

  • Marketed
  • Clinical Trials (Clinical Phases)

Global Oligonucleotide API Industry by End User:

  • Contract Manufacturing Organizations (CMOs)
  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Contract Development & Manufacturing Organizations (CDMOs)

Global Oligonucleotide API Industry by Region:

  • North America Oligonucleotide API Market
  • Latin America Oligonucleotide API Market
  • Europe Oligonucleotide API Market
  • East Asia Oligonucleotide API Market
  • South Asia & Pacific Oligonucleotide API Market
  • Middle East & Africa (MEA) Oligonucleotide API Market

Reach Out to Our Analyst For Your Queries
https://www.futuremarketinsights.com/ask-question/rep-gb-11933

Key Companies Profiled:

  • Jazz Pharmaceuticals, Inc.
  • Sarepta Therapeutics
  • Biogen
  • Dynavax Technologies
  • Akcea Therapeutics.
  • Alnylam Pharmaceuticals, Inc.

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these